Ambrx, Inc.
10975 North Torrey Pines Road
La Jolla
California
92037
United States
Tel: 858-875-2400
Website: http://www.ambrx.com/
About Ambrx, Inc.
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.
Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.
At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
83 articles about Ambrx, Inc.
-
Ambrx, Inc. and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer
6/17/2013
-
Ambrx, Inc. and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer
6/17/2013
-
Bristol-Myers Squibb Company Partners Again With Ambrx, Inc. in Up to $112 Million and Up ADC Collaboration
5/3/2013
-
Astellas Pharma Inc. Signs $300 Million Cancer Pact With Ambrx, Inc.
4/8/2013
-
Ambrx, Inc. Appoints Lawson Macartney, Ph.D., DVM, CEO
1/7/2013
-
Merck & Co., Inc. Bets Up to $303 Million on Ambrx, Inc.'s "Smart Bomb" Antibodies
6/18/2012
-
Bristol-Myers Squibb Company and Ambrx, Inc. Announce $24 Million Collaboration for Novel Biologics Programs in Diabetes and Heart Failure
9/22/2011
-
Ambrx, Inc. to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
6/21/2011
-
Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx, Inc.
5/25/2011
-
Ambrx, Inc. CEO Steve Kaldor Departs
7/13/2010
-
Wyeth (JOBS) and Ambrx, Inc. (JOBS) Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances
9/18/2009
-
Ambrx, Inc. Raises $10 Million
4/1/2009
-
Ambrx, Inc. and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
2/24/2009
-
Ambrx, Inc. Release: Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
11/13/2008
-
Ambrx, Inc. to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
11/5/2008
-
Ambrx, Inc. Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
2/26/2008
-
Ambrx, Inc. Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck & Co., Inc.
12/18/2007
-
Ambrx, Inc. Announces Drug Discovery Alliance With Eli Lilly and Company
12/17/2007
-
Ambrx, Inc. Initiates Phase I/II Clinical Trial Of Novel Human Growth Hormone Product Candidate
2/12/2007
-
Ambrx, Inc. Secures Additional $3 Million In Series C Financing
7/24/2006